Karen C Cravero

Dr. Karen C Cravero

University of Florida, Gainesville, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DCDavid Chu
David Chu
CPCostanza Paoletti
Costanza Paoletti
CGChristina Gersch
Christina Gersch
DVDustin A. VanDenBerg
Dustin A. VanDenBerg
DZDaniel J. Zabransky
Daniel J. Zabransky
BPBen Ho Park
Ben Ho Park
Purpose: Mutations in the estrogen receptor (ER)α gene, ESR1, have been identified in breast cancer metastases after progression on endocrine therapies. Because of limitations of metastatic biopsies, the reported frequency of ESR1 mutations may be underestimated. Here, we show a high frequency of ESR1 mutations using circulating plasma tumor DNA (ptDNA) from patients with metastatic breast cancer. Experimental Design: We retrospectively obtained plasma samples from eight patients with known ESR1 mutations and three patients with wild-type ESR1 identified by next-generation sequencing (NGS) of biopsied metastatic tissues. Three common ESR1 mutations were queried for using droplet digital PCR (ddPCR). In a prospective cohort, metastatic tissue and plasma were collected contemporaneously from eight ER-positive and four ER-negative patients. Tissue biopsies were sequenced by NGS, and ptDNA ESR1 mutations were analyzed by ddPCR. Results: In the retrospective cohort, all corresponding mutations were detected in ptDNA, with two patients harboring additional ESR1 mutations not present in their metastatic tissues. In the prospective cohort, three ER-positive patients did not have adequate tissue for NGS, and no ESR1 mutations were identified in tissue biopsies from the other nine patients. In contrast, ddPCR detected seven ptDNA ESR1 mutations in 6 of 12 patients (50%). Conclusions: We show that ESR1 mutations can occur at a high frequency and suggest that blood can be used to identify additional mutations not found by sequencing of a single metastatic lesion. Clin Cancer Res; 22(4); 993–9. ©2015 AACR.

28 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JCJustin Cidado
Justin Cidado
HWHong Yuen Wong
Hong Yuen Wong
DRD. Marc Rosen
D. Marc Rosen
ACAshley Cimino-Mathews
Ashley Cimino-Mathews
JGJoseph P. Garay
Joseph P. Garay
BPBen Ho Park
Ben Ho Park
Ki-67 is required for maintenance of cancer stem cells but not cell proliferation

1 October 2015 in Clinical Biochemistry
Verified
Journal Article
Closed access
PTPatricia Valda Toro
Patricia Valda Toro
BEBracha Erlanger
Bracha Erlanger
JBJulia A. Beaver
Julia A. Beaver
RCRory L. Cochran
Rory L. Cochran
DVDustin A. VanDenBerg
Dustin A. VanDenBerg
BPBen Ho Park
Ben Ho Park

27 October 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DZDaniel J. Zabransky
Daniel J. Zabransky
CYChristopher L. Yankaskas
Christopher L. Yankaskas
RCRory L. Cochran
Rory L. Cochran
HWHong Yuen Wong
Hong Yuen Wong
SCSarah Croessmann
Sarah Croessmann
BPBen Ho Park
Ben Ho Park
Significance: The discovery of human epidermal growth factor receptor 2 (HER2) missense mutations in breast and other cancers potentially make such tumors susceptible to current and future HER2-targeted therapies. However, the majority ofHER2mutations occur in HER2 nonamplified cancers, and whether these mutations will predict for sensitivity to HER2-directed therapies remains unknown. Using genome editing, the data presented here suggest thatHER2missense mutations are functionally distinct and require additional oncogenic input to impart cancerous phenotypes. These results suggest thatHER2missense mutations by themselves may not be reliable predictors of response to HER2-targeted therapies, a hypothesis currently being tested in genomically driven clinical trials.

30 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
WDW. Brian Dalton
W. Brian Dalton
EHEric Helmenstine
Eric Helmenstine
NWNoel Walsh
Noel Walsh
LGLukasz P. Gondek
Lukasz P. Gondek
DKDhanashree S. Kelkar
Dhanashree S. Kelkar
BPBen Ho Park
Ben Ho Park
Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.

24 November 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MMMorassa Mohseni
Morassa Mohseni
JCJustin Cidado
Justin Cidado
SCSarah Croessmann
Sarah Croessmann
KCKaren C Cravero
Karen C Cravero
ACAshley Cimino-Mathews
Ashley Cimino-Mathews
BPBen Ho Park
Ben Ho Park
Significance: Despite the widespread use and success of tamoxifen for treating ER-positive breast cancers, overcoming resistance to this drug remains an unmet need in clinical breast oncology. The results presented in this study demonstrate that overexpression of a novel gene, MACROD2 , can mediate tamoxifen resistance and estrogen independent growth in human breast cancers, and that amplification of MACROD2 in primary breast tumors is associated with worse overall survival.